Why Is ABCELLERA BIOLOGICS (ABCL) Stock Moving Today?

ABCL stock is moving lower today after opening with a small gap up, as intraday action shows a sharp decline from the morning high to a session low near $5.82. The stock is down nearly 8% from its opening price, trading at $5.87 in afternoon trading. The move follows a recent upgrade from Cantor Fitzgerald to Overweight at $11 and a separate price target of $11 from Benchmark, but the stock remains below both levels.

What Happened

Cantor Fitzgerald reissued an Overweight rating on AbCellera stock with a $11 price target, reaffirming its positive outlook despite the stock's recent pullback. This follows a preclinical research collaboration and licensing agreement between AbCellera and Jazz Pharmaceuticals, which aims to develop next-generation T-cell engaging multispecific antibodies. The partnership was announced earlier this year and is seen as a strategic move to expand AbCellera’s oncology pipeline. Additionally, AbCellera reported Q1 results that beat estimates, with revenue of $8.315 million and an EPS of -$0.14, which was better than expected. Despite these developments, the stock has declined over 19% in the past eight sessions.

What The Data Shows

The stock opened at $6.50, a modest 0.5% gap up from the previous close, but quickly reversed direction. Volume so far is 4.4 million shares, or 0.7 times the 3-month average, indicating moderate participation. The stock has traded between $2.75 and $8.44 over the past 52 weeks, and is currently near the lower end of that range. AbCellera remains unprofitable with a TTM net margin of -181.7% and a TTM revenue increase of 242.7%. A recent insider transaction shows John S. Montalbano, a director, bought shares on May 14, 2026, and another purchase was reported on May 18, 2026, totaling $95,000 in buys with no sells.

What To Watch

Investors should monitor the stock’s performance ahead of any further updates from the Jazz Pharmaceuticals collaboration or additional analyst commentary. No upcoming earnings date is provided, but coverage breadth and analyst ratings will remain key indicators.